ERBB3 and ovarian cancer: Additional assessments were conducted across the TMA, TCGA and CCLE data sets in breast and ovarian cancer types/subtypes, based on the noted differences in HER3 mRNA and protein expression between in vitro (CCLE) and in vivo (TMA) data, as well as those between mRNA and protein expression.